Trade Summary

1 week ago, WALSH COLIN, serving as Dir at Attovia Therapeutics, Inc. (ATTO), purchased 585,000 shares at $17.58 per share, for a total transaction value of $10,285,000.00. Following this transaction, WALSH COLIN now holds 3,020,632 shares of ATTO.

This purchase represents a 24.02% increase in WALSH COLIN's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, August 5, 2026 and publicly disclosed via SEC Form 4 filing on Friday, August 14, 2026 (accepted Aug 13, 9:52 PM ET), 9 days after the trade was made.

Attovia Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.